Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Go Asari"'
Autor:
Sakiko Tabata Kuribayashi, Takuya Yamagishi, Naoki Suzuki, Go Asari, Rieko Abo, Harumi Yamamoto, Kazunori Yasutomi, Tsukasa Ohara, Yasuko Tachibana, Tomoe Shimada, Tomimasa Sunagawa
Publikováno v:
Public Health in Practice, Vol 6, Iss , Pp 100403- (2023)
Objectives: As social restrictions of COVID-19 are being eased worldwide, preventing SARS-CoV-2 transmission among staff members and customers in dining facilities is essential to continuously running business because restaurants and bars are high-ri
Externí odkaz:
https://doaj.org/article/a2a3c7ca5bc04654afbc18d60cd0f09e
Autor:
Yasutaka Kakinoki, Kazuki Yamada, Yoko Tanino, Keiko Suzuki, Takaya Ichikawa, Naoki Suzuki, Go Asari, Ai Nakamura, Shin Kukita, Akito Uehara, Seisuke Saito, Shohei Kuroda, Hidemitsu Sakagami, Yuuki Nagashima, Kae Takahashi, Satoshi Suzuki
Publikováno v:
International Journal of Infectious Diseases, Vol 117, Iss , Pp 189-194 (2022)
ABSTRACT: Background: Recent data from clinical trials suggest that antibody cocktail therapy, which combined casirivimab and imdevimab, is linked to the reduction of the risk of hospitalization or death among high-risk patients with COVID-19. Howeve
Externí odkaz:
https://doaj.org/article/ecb306fb9eca44d887f35cf0a52e4838
Autor:
Sakiko, Tabata, Takuya, Yamagishi, Yuuki, Tsuchihashi, Tomimasa, Sunagawa, Naoki, Suzuki, Go, Asari, Rieko, Abo, Harumi, Yamamoto, Kazunori, Yasutomi, Ohara, Tsukasa, Yasuko, Tachibana, Okub, Kazuhiro, Ohno, Yuta, Yoshihiro, Fujiya, Yusuke, Kobayashi, Hajime, Kamiya
Publikováno v:
Pediatric Infectious Disease Journal. 41:e451-e452
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74c37d830fee0fa1c2c6ad1fdb9e7f6c
https://doi.org/10.1097/inf.0000000000003652
https://doi.org/10.1097/inf.0000000000003652
Autor:
Akito Uehara, Kazuki Yamada, Yuuki Nagashima, Go Asari, Naoki Suzuki, Keiko Suzuki, Ai Nakamura, Yasutaka Kakinoki, Yoko Tanino, Seisuke Saito, Hidemitsu Sakagami, Kae Takahashi, Shin Kukita, Satoshi Suzuki, Takaya Ichikawa, Shohei Kuroda
BackgroundRecent data from clinical trial suggest that antibody cocktail therapy, a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to rapidly reduce the viral load and markedly decrease the risk of hospitalization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7861d6c8bbc842ef016ed378c7a52a3f
https://doi.org/10.1101/2021.10.10.21264589
https://doi.org/10.1101/2021.10.10.21264589
Autor:
Akito Uehara, Go Asari, Ai Nakamura, Naoki Suzuki, Takaya Ichikawa, Hidemitsu Sakagami, Yoko Tanino, Yuuki Nagashima, Kazuki Yamada, Kae Takahashi, Shohei Kuroda, Seisuke Saito, Yasutaka Kakinoki, Keiko Suzuki, Shin Kukita, Satoshi Suzuki
Publikováno v:
Fortune Journal of Health Sciences.
Background Recent data from clinical trial suggest that antibody cocktail therapy, a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to rapidly reduce the viral load and markedly decrease the risk of hospitalization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::765dd9763941648d1494b61d7440d561
https://doi.org/10.26502/fjhs.040
https://doi.org/10.26502/fjhs.040